Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Intellia Therapeutics (NTLA) Non Operating Investment Income (2019 - 2025)

Historic Non Operating Investment Income for Intellia Therapeutics (NTLA) over the last 7 years, with Q3 2025 value amounting to $3.4 million.

  • Intellia Therapeutics' Non Operating Investment Income fell 2275.38% to $3.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$429000.0, marking a year-over-year increase of 9785.3%. This contributed to the annual value of -$32.6 million for FY2024, which is 99587.35% down from last year.
  • Latest data reveals that Intellia Therapeutics reported Non Operating Investment Income of $3.4 million as of Q3 2025, which was down 2275.38% from $1.3 million recorded in Q2 2025.
  • Intellia Therapeutics' Non Operating Investment Income's 5-year high stood at $4.5 million during Q3 2024, with a 5-year trough of -$20.4 million in Q2 2024.
  • For the 5-year period, Intellia Therapeutics' Non Operating Investment Income averaged around -$1.2 million, with its median value being -$13000.0 (2021).
  • In the last 5 years, Intellia Therapeutics' Non Operating Investment Income plummeted by 9310000.0% in 2022 and then surged by 303521.13% in 2024.
  • Over the past 5 years, Intellia Therapeutics' Non Operating Investment Income (Quarter) stood at -$2.0 million in 2021, then surged by 275.91% to $3.4 million in 2022, then tumbled by 42.13% to $2.0 million in 2023, then tumbled by 255.19% to -$3.1 million in 2024, then surged by 211.58% to $3.4 million in 2025.
  • Its Non Operating Investment Income stands at $3.4 million for Q3 2025, versus $1.3 million for Q2 2025 and -$2.1 million for Q1 2025.